行情

ICPT

ICPT

Intercept
NASDAQ

实时行情|Nasdaq Last Sale

60.18
+1.78
+3.05%
已收盘, 17:25 04/02 EDT
开盘
59.03
昨收
58.40
最高
61.97
最低
57.69
成交量
48.36万
成交额
--
52周最高
125.00
52周最低
47.57
市值
19.77亿
市盈率(TTM)
-5.5209
分时
5日
1月
3月
1年
5年

分析师评级

21位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ICPT价格均价为151.90,最高价位257.00,最低价为89.00。

EPS

ICPT 新闻

更多
  • Benzinga's Top Upgrades, Downgrades For April 2, 2020
  • Benzinga · 22小时前
  • Morgan Stanley likes Bristol-Myers Squibb in premarket analyst action
  • Seeking Alpha - Article · 1天前
  • Chardan Capital Initiates Coverage On Intercept Pharmaceuticals with Buy Rating, Announces Price Target to $145
  • Benzinga · 1天前
  • Is Intercept (ICPT) Stock a Solid Choice Right Now?
  • Zacks · 1天前

所属板块

生物技术和医学研究
+3.33%
制药与医学研究
+2.79%

热门股票

代码
价格
涨跌幅

ICPT 简况

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.
展开

微牛提供Intercept Pharmaceuticals Inc(NASDAQ-ICPT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ICPT股票新闻,以帮助您做出投资决策。